Trial Profile
A Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SCT400, a Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With CD20+ B-cell Non Hodgkin's Lymphoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ripertamab (Primary)
- Indications B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Sinocelltech
- 05 Aug 2014 New trial record